Literature DB >> 11266415

Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose.

T Gee1, J M Andrews, J P Ashby, G Marshall, R Wise.   

Abstract

The pharmacokinetics and tissue penetration of gemifloxacin were determined during a 24 h period following oral administration of a single 320 mg dose to each of 10 healthy male volunteers. Concentrations of the drug in plasma, inflammatory blister fluid and urine were determined using a microbial assay. A peak plasma concentration (mean +/- S.D.) of 2.33 +/- 0.5 mg/L was reached at 1.20 +/- 0.4 h. Mean penetration into inflammatory fluid was 61.19 +/- 10.4%. A peak concentration of 0.74 +/- 0.3 mg/L was reached in the inflammatory fluid at a mean time of 3.40 +/- 1.7 h. The mean elimination half-life from serum and inflammatory fluid was 5.94 +/- 0.4 and 6.27 +/- 2.4 h, respectively. Urinary excretion of the drug at 24 h post-dose was 36.11% of the total given. These results demonstrate that gemifloxacin penetrates into the site of inflammation and reaches sufficient concentrations to inhibit many pathogens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11266415     DOI: 10.1093/jac/47.4.431

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Concentrations of gemifloxacin at the target site in healthy volunteers after a single oral dose.

Authors:  Florian Islinger; Rene Bouw; Mathias Stahl; Edith Lackner; Petra Zeleny; Martin Brunner; Markus Müller; Hans Georg Eichler; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

2.  Comparative pharmacokinetics and bioavailability of gemifloxacin administered as an intravenous 200 mg formulation or an oral 320 mg tablet.

Authors:  Mi Jo Kim; Hyeong-Seok Lim; Sang-Heon Cho; Kyun-Seop Bae
Journal:  Clin Drug Investig       Date:  2014-03       Impact factor: 2.859

3.  Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.

Authors:  Genoveva Yague; Julia E Morris; Xiao-Su Pan; Katherine A Gould; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

4.  Identifying Vancomycin as an Effective Antibiotic for Killing Borrelia burgdorferi.

Authors:  Xiaoqian Wu; Bijaya Sharma; Samantha Niles; Kathleen O'Connor; Rebecca Schilling; Nicole Matluck; Anthony D'Onofrio; Linden T Hu; Kim Lewis
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

5.  Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis.

Authors:  Philippe Cottagnoud; Fernando Acosta; Marianne Cottagnoud; Martin G Täuber
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells.

Authors:  Bijaya Sharma; Autumn V Brown; Nicole E Matluck; Linden T Hu; Kim Lewis
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

7.  Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.

Authors:  Luke Lin; Li-Wen Chang; Cheng-Yuan Tsai; Ching-Hung Hsu; David T Chung; William S Aronstein; Funmi Ajayi; Barbara Kuzmak; Robert A Lyon
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

8.  Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.

Authors:  Die Cheng; Wei-Ren Xu; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.